Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma.

Date publication

janvier 2019

Journal

PloS one

Auteurs

Membres identifiés du Cancéropôle Est :
Pr HARLE Alexandre , Dr LEROUX Agnès , Pr MERLIN Jean-Louis , Dr GILSON Pauline

Tous les auteurs :
Franczak C, Dubouis L, Gilson P, Husson M, Rouyer M, Demange J, Leroux A, Merlin JL, Harlé A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30811471

Résumé

KRAS and NRAS mutations are identified resistance mutations to anti-epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancer. BRAF status is also routinely assessed for its poor prognosis value. In our institute, next-generation sequencing (NGS) is routinely used for gene-panel mutations detection including KRAS, NRAS and BRAF, but DNA quality is sometimes not sufficient for sequencing. In our routine practice, Idylla platform is used for the analysis of samples that don't reach sufficient quality criteria for NGS assay.

Référence

PLoS ONE. 2019 ;14(2):e0212801